Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial

J. Harding; J. Cleary; G. Shapiro; I. Braña; V. Moreno; D. Quinn; M. Borad; S. Loi; I. Spanggaard; S. Stemmer; M. Dujka; R. Cutler; F. Xu; L. Eli; S. Macia; A. Lalani; R. Bryce; F. Meric Bernstam; D. Solit; D. Hyman; S. Piha-Paul

doi:10.1093/annonc/mdz154.004

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial

J. Harding, J. Cleary, G. Shapiro, I. Braña, V. Moreno, D. Quinn, M. Borad, S. Loi, I. Spanggaard, S. Stemmer, M. Dujka, R. Cutler, F. Xu, L. Eli, S. Macia, A. Lalani, R. Bryce, F. Meric Bernstam, D. Solit, D. HymanS. Piha-Paul

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	iv127
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz154.004
State	Published - Jul 1 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz154.004

Cite this

Harding, J., Cleary, J., Shapiro, G., Braña, I., Moreno, V., Quinn, D., Borad, M., Loi, S., Spanggaard, I., Stemmer, S., Dujka, M., Cutler, R., Xu, F., Eli, L., Macia, S., Lalani, A., Bryce, R., Bernstam, F. M., Solit, D., ... Piha-Paul, S. (2019). Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv127. https://doi.org/10.1093/annonc/mdz154.004

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. / Harding, J.; Cleary, J.; Shapiro, G. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, 01.07.2019, p. iv127.

Research output: Contribution to journal › Article › peer-review

Harding, J, Cleary, J, Shapiro, G, Braña, I, Moreno, V, Quinn, D, Borad, M, Loi, S, Spanggaard, I, Stemmer, S, Dujka, M, Cutler, R, Xu, F, Eli, L, Macia, S, Lalani, A, Bryce, R, Bernstam, FM, Solit, D, Hyman, D & Piha-Paul, S 2019, 'Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, pp. iv127. https://doi.org/10.1093/annonc/mdz154.004

@article{9d5389e2b7b84dafa408efd399068e1e,

title = "Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial",

author = "J. Harding and J. Cleary and G. Shapiro and I. Bra{\~n}a and V. Moreno and D. Quinn and M. Borad and S. Loi and I. Spanggaard and S. Stemmer and M. Dujka and R. Cutler and F. Xu and L. Eli and S. Macia and A. Lalani and R. Bryce and Bernstam, {F. Meric} and D. Solit and D. Hyman and S. Piha-Paul",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz154.004",

language = "English (US)",

volume = "30",

pages = "iv127",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Treating HER2-mutant advanced biliary tract cancer with neratinib

T2 - benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial

AU - Harding, J.

AU - Cleary, J.

AU - Shapiro, G.

AU - Braña, I.

AU - Moreno, V.

AU - Quinn, D.

AU - Borad, M.

AU - Loi, S.

AU - Spanggaard, I.

AU - Stemmer, S.

AU - Dujka, M.

AU - Cutler, R.

AU - Xu, F.

AU - Eli, L.

AU - Macia, S.

AU - Lalani, A.

AU - Bryce, R.

AU - Bernstam, F. Meric

AU - Solit, D.

AU - Hyman, D.

AU - Piha-Paul, S.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85079742673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079742673&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz154.004

DO - 10.1093/annonc/mdz154.004

M3 - Article

C2 - 32085018

SN - 0923-7534

VL - 30

SP - iv127

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this